Skip to main content

Table 1 Participant characteristics at baseline

From: A novel Aβ isoform pattern in CSF reflects γ-secretase inhibition in Alzheimer disease

  Placebo LY450139, 100 mg LY450139, 140 mg
Characteristic ( n = 10) ( n = 15) ( n = 10)
Demographics    
Age, mean (SD, years) 69.1 (8.81) 72.4 (8.13) 68.8 (9.02)
Female sex, number (%) 5 (50) 10 (66.6) 4 (40)
APOE e4 carriers, number (%) 8 of 10 (80) 11 of 13 (84.6) 7 of 9 (77.8)
Clinical scores, mean (SD)    
MMSE 18.3 (4.0) 22 (3.6) 24.9 (1.4)
ADCS-ADL 61.9 (7.3) 67.7 (8.4) 70.6 (7.8)
ADAS-Cog 11 26.9 (10.0) 19.9 (6.3) 17.9 (5.8)
  1. ADAS-Cog 11, Alzheimer's Disease Assessment Scale Cognitive Subscale; ADCS-ADL, Alzheimer's Disease Cooperative Study Activities of Daily Living Scale; APOE, apolipoprotein E; MMSE, Mini-Mental State Examination.